Print

Orchid Chemicals & Pharmaceuticals Ltd.
Unaudited Financial Results for three months ended June 30, 2006
(Rs.Lakhs)
   
Standalone Results
Consolidated Results
S.No
Particulars
Three months ended
30-June-06
(Unaudited)
Three months ended
30-June-05
(Unaudited)
Year ended 31-Mar-06 (Audited)
Three months ended 30-June-06 (Unaudited)
Three months ended 30-June-05 (Unaudited)
Year ended 31-Mar-06 (Audited)
1
 Sales and Operating Income
20170.98
17025.75
88876.64
21264.90
18782.48
95193.99
2
 Other Income
78.14
43.82
132.73
74.99
36.96
121.90
3
 Total Expenditure
14369.81
12483.54
62949.30
15741.86
14620.16
71448.65
a) Decrease/(Increase) in Stock in trade
(3348.94)
(2329.19)
(1912.72)
(3481.59)
(3206.49)
(2048.83)
b) Consumption of raw materials
10506.96
9391.23
36439.22
11611.60
11743.55
42948.56
c) Staff Cost
1717.67
1408.39
6521.18
1887.39
1439.31
6963.89
d) Other Expenditure
5494.12
4013.11
21901.62
5724.46
4643.79
23585.03
4
Profit before Interest, Depreciation & Tax (1+2-3)
5879.31
4586.03
26060.07
5598.03
4199.28
23867.24
5
 Interest and Finance Charges
2202.85
2076.12
8701.32
2231.53
2092.97
8784.48
6
 Depreciation / Amortisation
1932.37
1690.53
8297.57
1998.26
1746.16
8581.76
7
 Profit before tax (4-5-6)
1744.09
819.38
9061.18
1368.24
360.15
6501.00
8
 Provision for Taxation
    Current Tax
-
46.00
-
-
46.00
0.00
    Deferred Tax
250.00
-
590.00
250.00
-
590.00
    Fringe Benefit Tax
35.00
40.00
181.00
35.00
40.00
181.00
9
 Net Profit (7-8)
1459.09
733.38
8290.18
1083.24
274.15
5730.00
10
 Paid- up Equity Share Capital (Face value of Rs. 10 each)
6581.17
3414.37
6461.82
6581.17
3414.37
6461.82
11
 Reserves excluding Revaluation Reserves
72040.71
71096.88
12
 Basic Earnings per Share (EPS) Rs.**
2.22*
1.43*
14.85
1.65*
0.54*
10.27
13
 Diluted Earnings per Share (EPS) Rs.**
1.98*
1.42*
13.64
1.47*
0.53*
9.43
               
* EPS is for the period (not annualised) after providing for taxes.
** EPS for earlier periods adjusted for the bonus issue.
  • The above financial results were taken on record by the Board of Directors at its meeting held on Thursday, July 27, 2006.
  • The Company's increasing level of exports to regulated markets is in the form of finished dosage forms (formulations) which utilised the Company's active pharmaceutical ingredients (bulk drugs). In view of the integration of bulk actives and formulations business segments, the Company considers the business as one integrated business of "Pharmaceutical products" and hence no separate segmental reporting is provided.
  • The standalone accounts have been subjected to limited review by the Statutory Auditors.
  • The Allotment Committee of the Board has allotted shares as follows:
    - 4,14,744 and 7,37,325 equity shares on April 18, 2006 and April 28, 2006 on conversion of US$ 2,250,000 and US$ 4,000,000 Zero-Coupon FCCBs respectively
    - 3,475 shares (2250 shares at an adjusted price of Rs.162.24/- per share and 1225 shares at an adjusted price at Rs.168/- per share) to employees under ORCHID ESOP 1999 Scheme on April 28, 2006
    - 35,000 equity shares at an adjusted price of Rs. 226.28/- to Promoter / Promoter group(s) on May 31, 2006 on conversion of warrants
    - 3,015 shares (600 shares at an adjusted price of Rs.162.24/- per share, 1177 shares at an adjusted price of Rs.168/- per share and 1238 shares at an adjusted price of Rs. 200.44/- per share) to employees under ORCHID ESOP 1999 Scheme on May 31, 2006.
  • The Company received 15 complaints during the quarter ended June 30, 2006 from the shareholders, all the complaints have been resolved and no complaints were pending as on June 30, 2006.
  • Figures for the previous periods have been regrouped wherever necessary.

Place : Chennai
Date : July 27, 2006

For and on behalf of the Board

K.Raghavendra Rao
Managing Director